What is the clinical efficacy and acceptability of non-surgical brain stimulation 29 protocols for the acute treatment of major depressive episodes in adults? 30 31 Findings: In this network meta-analysis, 10 out of 18 treatment protocols were associated with 32 higher response rates relative to sham, most notably bitemporal and high-dose right unilateral 33 electroconvulsive therapy. All treatment protocols were at least as acceptable as sham 34 treatment. 35
Major depression is a highly prevalent and debilitating illness 1 with considerable disease 95 burden 2 . Its disease course is often recurrent and can become chronic, with relapse rates of up 96 to 80% within one year of remission 3 . Multiple treatment strategies are available -97 pharmacological interventions and psychological therapies are the most frequently prescribed 98 treatments. However, the effectiveness of these treatments remains limited and less than 50% 99 of patients respond to an initial course of drug treatment 4 . A significant number of patients do 100 not tolerate pharmacotherapy because of undesired effects including sexual dysfunction, weight 101 gain and insomnia 5,6 . Combination strategies with multiple pharmacological agents increase the 102 risk for adverse events and drug interactions 7 . These factors limit medication-adherence and 103 potentially cause discontinuation of treatment 8 . Similarly, psychological therapies are not 104 effective for every patient and may also be associated with undesired effects 9 . 105 106
Non-surgical brain stimulation techniques including electroconvulsive therapy (ECT) and 107 repetitive transcranial magnetic stimulation (rTMS) have been applied as tertiary treatments or 108 are considered to be alternative or add-on treatments for major depressive episodes. Over the 109 past decade, novel modifications of standard rTMS have been developed to optimize treatment: 110 deep transcranial magnetic stimulation (dTMS), theta burst stimulation (TBS), priming 111 transcranial magnetic stimulation (pTMS), accelerated transcranial magnetic stimulation 112 (aTMS) and synchronised transcranial magnetic stimulation (sTMS). Clinical trials have also 113 examined the antidepressant efficacy of magnetic seizure therapy (MST) and transcranial direct 114 current stimulation (tDCS) (Supplement 1). 115 116
Previous meta-analyses have examined the clinical efficacy and acceptability of brain 117 stimulation compared to placebo 10 or within pairs of active treatments 11 . However, these 118 approaches provide limited insights into the overall treatment hierarchy because the available 119 evidence was not synthesised in one step. Moreover, the absence of head-to-head clinical trials 120 for some treatment comparisons creates uncertainty for decision-makers. 121 122
Network meta-analysis (NMA) includes both direct and indirect treatment comparisons 12 , and 123 should be regarded as the highest level of evidence in treatment guidelines 13 and may overcome 124 a lack of head to head evaluation. Two NMAs of brain stimulation therapies for major 125 depressive episodes have been published but were limited in scope of included 126 interventions 14, 15 The primary aim of this study is to estimate the efficacy and acceptability of non-surgical brain 135 stimulation protocols for the acute treatment of major depressive episodes in adults 136 participating in randomised clinical trials (RCTs). 137
We followed the PRISMA guidelines for NMA 16 Studies had to include at least two of the following treatments: tDCS, rTMS, TBS, dTMS, 156 sTMS, pTMS, aTMS, ECT, MST or sham. For rTMS, protocols were grouped according to coil 157 location and stimulation frequency: high-frequency stimulation of the left dorsolateral 158 prefrontal cortex (DLPFC; HF-L), high-frequency stimulation of the right DLPFC (HF-R), low-159 frequency stimulation of the right DLPFC (LF-R), low-frequency stimulation of the left DLPFC 160 (LF-L) and bilateral stimulation of the DLPFC (BL). TBS protocols were grouped in a similar 161 fashion: intermittent stimulation of the left DLPFC (iTBS), continuous stimulation of the right 162 DLPFC (cTBS) and bilateral stimulation of the DLPFC (blTBS). Finally, ECT protocols were 163 grouped according to electrode placement (BF = bifrontal; BT = bitemporal; RUL = right 164 unilateral), and for RUL ECT also according to electrical dosage (H-RUL = high-dose right 165 unilateral; LM-RUL = low to moderate-dose right unilateral). For multi-arm trials, treatment 166 groups that could not be included individually were combined 19 . All sham controls were merged 167 into one node. Supplement 2 shows the network of potential treatment comparisons. We assume 168 that any patient enrolled in one of the trials included in our review is, in principle, equally likely 169 to be randomised to any other trial in the network. 170 171 excluded trials in which pharmacological or psychological treatments were co-initiated with 173 brain stimulation. 174 175 Data synthesis 215 We computed odds ratios (ORs; Mantel-Haenszel method) and standardised mean differences 216 (SMD; Hedge's g) with 95% confidence intervals (CIs) to estimate effect sizes for categorical 217 and continuous outcomes, respectively. The primary outcome measure of efficacy was 218 response, defined in most trials as a ≥ 50% reduction in depressive symptoms at primary 219 treatment endpoint. Remission was our secondary outcome measure of efficacy, according to 220 the criteria used in each trial (e.g. HDRS ≤ 7 at primary treatment endpoint). Continuous post-221 treatment depression severity scores constituted our tertiary efficacy outcome measure. If trials 222 reported data on both HDRS and MADRS, the HDRS data were selected for analyses to 223 facilitate comparability between trials. In case of multiple HDRS versions, the original 17-item 224 version was analysed. Data based on the intention-to-treat (ITT) or modified intention to treat 225 (mITT) sample were preferred over data based on completers for all analyses. 226 227
Search methods for identification of studies

Pairwise meta-analysis. 228
We conducted frequentist random-effects meta-analyses of all direct treatment comparisons, 229 allowing for heterogeneity in treatment effects between studies. All pairwise analyses were 230 conducted using the 'meta' package 21 in RStudio 1.0.143. 231 232
Statistical heterogeneity within each pairwise comparison was estimated using the I 2 statistic, 233 with values of 25%, 50% and 75% representing little, substantial and severe level of 234 heterogeneity 22 . When severe heterogeneity was exhibited, this was investigated using 235 subgroups to explore the effect modifiers. Subgroups included treatment resistance, diagnosis, 236 hospitalisation status and exclusion of patients with psychotic features. 237 238
Network meta-analysis. 239 connectivity 23 . NMAs were fit within a frequentist framework using a multivariate random-241 effects meta-analysis model 24,25 that accounts for the correlations between effect sizes in trials 242 with more than two groups. 243 244
We assumed network consistency and a common heterogeneity parameter across all treatment 245 contrasts. Relative ORs or SMDs and 95% CIs for all treatment comparisons were presented in 246 league tables. We also present relative treatment effects with 95% CIs and 95% prediction 247 intervals (PrIs) for all sham comparisons in forest plots. To obtain treatment hierarchies, we 248 computed ranking probabilities for all ranks and outcomes using a parametric bootstrap 249 procedure with 10,000 resamples 25 . All NMAs were conducted using the 'mvmeta' 26,27 and 250 'network' 28 packages in Stata SE 15.0. 251 252
We assessed the transitivity assumption by comparing the distribution/frequency of potential 253 effect modifiers across treatment comparisons: continuous (depression severity at baseline, age, 254 percent female) and categorical (treatment resistance, diagnosis, hospitalisation status, 255 exclusion of patients with psychotic features and treatment strategy). 256 257
Assuming equivalence of direct and indirect evidence (i.e. consistency) in NMA may lead to 258 inaccurate conclusions when there is evidence for significant inconsistency 25 . We assessed the 259 assumption of consistency by fitting a design-by-treatment interaction model 24,25 that accounts 260 for loop and design inconsistencies and provides a global Wald test to evaluate inconsistency 261 in the entire network. 262 263
We also computed inconsistency factors (IFs) and 95% CIs for each closed triangular and 264 quadratic loop within treatment networks to estimate absolute differences between direct and 265 indirect evidence. We used a method of moments estimator of loop-specific heterogeneity, 266 assuming a common heterogeneity parameter for all comparisons within the same loop. 267 268
Sensitivity analysis. 269
We conducted two sensitivity analyses to assess the robustness of our findings for response and 270 all-cause discontinuation rates: (1) trials that examined tDCS were excluded and (2) trials with 271 high overall risk of bias were excluded. 272
Results
273
The PRISMA flowchart is presented in Figure Overall, N=6,750 patients were randomised to treatment. The mean age was 47.9 years and 279 59% (n = 3,545) were women. The median study sample size was 40 patients (range=6-414). 280
The risk of bias assessment is presented in Supplement 6. Briefly, 23.9% of the included trials 281 were considered low risk, while 57.5% and 18.6% were categorised as unclear or high risk, 282 respectively. 283 284
Most trials (80.9%) recruited only patients with treatment resistant depression (TRD), typically 285 defined as a minimum of two failed pharmacological treatments. Only 12.8% recruited both 286 TRD and non-TRD patients; the remaining 6.4% recruited patients with non-TRD. 58.5% of 287 the studies excluded patients with psychotic features. 49.1% recruited patients with MDD only. 288
For the trials that recruited both patients with MDD and bipolar depression (46.2%), few 289 patients were diagnosed with bipolar depression. 48.8% of trials recruited outpatients only, 290 whereas 29.1% and 22.1% recruited inpatients only or both outpatients and inpatients, 291 respectively. In 63.2% of the studies brain stimulation was an add-on treatment to stable 292 pharmacotherapy in most, if not all, patients. Baseline depression severity, percent female and 293 age were similar across most treatment comparisons. As such, the assumption of transivity is 294 likely to hold in our data. 295 296
Pairwise meta-analysis to -0.77 [max]). BL rTMS was more efficacious than sham when considering response (4.93, 301 2.78-8.75; I 2 =0%) and remission (4.67, 1.84-11.84; I 2 =0%), while iTBS was more efficacious 302 than sham in terms of response (4.25, 1.22-14.84; I 2 =0%). There were few differences between 303 active treatments. Most notably, BT ECT was more efficacious than LM-RUL ECT across all 304 outcomes (ORs=3.87 [min] to 6.67 [max]; SMD=-0.88, -1.28 to -0.49; I 2 =0%). In terms of all-305 cause discontinuation, we found no differences between active treatments and sham and 306 heterogeneity between trials could not be explained by stratifying analyses according to 307 hospitalisation status, psychotic symptoms, treatment resistance or diagnosis. 308 309
Network meta-analysis 310 The results of the NMA of the primary outcome of efficacy (response) and acceptability (all-311 cause discontinuation) are presented in Table 1 Comparing active treatments, BT ECT was associated with higher response than BF ECT, LM-330 RUL ECT, LF-L rTMS, cTBS and dTMS. H-RUL ECT was associated with higher response 331 than LM-RUL ECT and cTBS. pTMS and BL rTMS were more efficacious than cTBS. No 332 other significant differences between active treatments were found (Table 1) . 333 334
All-cause discontinuation rates were available for 227 treatment arms (n = 6,362), including all 335 (Table 1) . All treatments were at least as acceptable as sham and these conclusions did 
Inconsistency. 357
Fitting the design-by-treatment interaction model provided no evidence for significant 358 inconsistency for response, remission and all-cause discontinuation (global Wald tests: p = 359 0.42-0.99). However, there was some evidence for inconsistency in the post-treatment 360 depression severity network (global Wald test: p = 0.09). We present inconsistency plots for 361 each outcome in Supplement 12. For our primary outcome measure of efficacy (response), we 362 found evidence for inconsistency in 3/21 (14%) loops, while there was no evidence for 363 inconsistency for all-cause discontinuation. 364 365
Sensitivity analysis 366
Excluding trials that investigated tDCS did not materially change our results and overall 367 conclusions (Supplement 13). When trials with high overall risk of bias were excluded, MST 368 and iTBS were no longer associated with higher response than sham. There was also no 369 evidence that pTMS was associated with fewer drop-outs than any other treatment in the 370 network. 371 This is the most comprehensive systematic review and network meta-analysis of non-surgical 373 brain stimulation for the acute treatment of major depressive episodes in adults. We included 374 data from 113 clinical trials including 6,750 patients with MDD or bipolar depression who were 375 randomised to 18 distinct treatment protocols or sham. The quality of the evidence was typically 376 of low or unclear risk of bias (92 out of 113 trials; 81.4%). 377 378
Our findings provide evidence for the antidepressant efficacy of ECT. Previous comparative 379 analyses did not consistently favour BT ECT or RUL ECT, and it has been suggested that RUL 380 ECT needs to be delivered at multiples of seizure threshold to be effective 31, 32 . Trials that 381 employed electrical dosages at or just above seizure threshold may have underestimated 382 treatment effects. Our findings support this view. We found no evidence of differences in We found limited evidence in support of the more recent treatment modalities. Compared to 402 sham, iTBS and pTMS were associated with improved response and remission in NMA, while 403 blTBS was associated with higher response. However, when considering data from pairwise 404 direct comparisons only, the evidence in favour of iTBS compared to sham was limited to 405 higher response. With respect to dTMS we found evidence of antidepressant efficacy across 406 outcome measures in pairwise analyses but not in NMA. Considering that the direct evidence 407 is based on data from two RCTs 40,41 only, further investigations are warranted. We found no 408 evidence suggesting that cTBS, aTMS and sTMS are effective treatments for major depressive 409 episodes. However, these findings need to be treated with caution due to the limited number of 410 included studies. Finally, while previous meta-analyses of the antidepressant efficacy of tDCS 411 yielded inconsistent results 10,42-46 , we found tDCS to be efficacious across outcomes in both 412 pairwise and network meta-analyses. 413 414
There was little evidence for differences in all-cause discontinuation between active treatments 415 and sham. The notable exception was pTMS for which lower drop-out rates were reported. 416
However, we did not examine specific undesired and adverse effects associated with treatment. 417 418
Limitations were that most included studies exhibited unclear risk of bias, particularly with 419 respect to random sequence generation and allocation concealment. Overall risk of bias was 420 deemed high in 21 trials (18.6%). In a sensitivity analysis excluding these trials we found that 421 iTBS and MST were no longer associated with higher response than sham. Moreover, we found 422 no evidence of differences in all-cause discontinuation between pTMS and other treatments. 423 424
There was some evidence for statistical heterogeneity within pairwise comparisons and a small 425 number of loops in our NMA of response suggested inconsistency between direct and indirect 426 sources of evidence. To facilitate interpretation of our results taking the magnitude of 427 heterogeneity into account, we presented predictive intervals for all sham-comparisons. For 428 MST, iTBS and tDCS the estimate of a future trial might suggest that these treatment protocols 429 are no more efficacious than sham. 430 431 While several RCTs have compared different rTMS or different ECT protocols, few trials have 432 compared novel brain stimulation techniques to ECT. A conceivable explanation is that rTMS 433 and related interventions require no anaesthetic but a higher level of cooperation from the 434 patient, whereas ECT can be prescribed to patients who are more severely depressed. However, 435 most trials that were included in our analyses were conducted after multiple pharmacotherapies 436 had failed and patient characteristics did not materially differ between most treatment 437 comparisons. Trials that examined tDCS were excluded in a sensitivity analysis because these 438 studies showed some differences with other treatment comparisons and because tDCS is a less 439 invasive treatment protocol. Excluding these studies did not materially change our results. 440 Finally, we focused on the acute antidepressant effects at primary study endpoint and our 442 conclusions might not apply to the long-term effects of non-surgical brain stimulation. 443
Continuation and maintenance treatment will need to be reviewed separately. Salanti, G. Indirect and mixed-treatment comparison, network, or multiple-treatments 521 meta-analysis: many names, many benefits, many concerns for the next generation 
